STI571 (Gleevec™) as a paradigm for cancer therapy

Research output: Contribution to journalReview articlepeer-review

259 Scopus citations


STI571 (Gleevec™, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection and possible mechanisms of resistance to STI571. Finally, the potential use of STI571 with different tumors and the translation of this paradigm to other malignancies are explored.

Original languageEnglish (US)
Pages (from-to)S14-S18
JournalTrends in Molecular Medicine
Issue number4 SUPPL.
StatePublished - 2002

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology


Dive into the research topics of 'STI571 (Gleevec™) as a paradigm for cancer therapy'. Together they form a unique fingerprint.

Cite this